Xenikos B.V.

Over Xenikos B.V.

Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company’s lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.

Trefwoorden

• Biopharmacy
• Biotechnology
• Clinical Development
• Drug Development
• Immunotherapy
• Medicine

Adres

• Hoofdkantoor

  Wilhelminasingel 146524 NijmegenGelderland, Nederland